focusIR May 2024 Investor Webinar: Blue Whale, Kavango, Taseko Mines & CQS Natural Resources. Catch up with the webinar here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksAstrazeneca Share News (AZN)

Share Price Information for Astrazeneca (AZN)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 12,166.00
Bid: 11,500.00
Ask: 12,200.00
Change: 0.00 (0.00%)
Spread: 700.00 (6.087%)
Open: 0.00
High: 0.00
Low: 0.00
Prev. Close: 12,166.00
AZN Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

European shares rise tentatively

Fri, 23rd Dec 2022 09:43

Welcome to the home for real-time coverage of markets brought to you by Reuters reporters. You can share your thoughts with us at

EUROPEAN SHARES RISE TENTATIVELY (0915 GMT)

European indices are enjoying a moderate lift this morning, as the STOXX 600 ticked up in the first hour of trading and is now around 0.28% higher.

The top riser of the index is Danish biotech Bavarian Nordic, with shares up 5.8% after the company said it had signed a deal worth up to $83 million with the U.S Department of Defense.

Swiss drugmaker Roche Holding is providing the biggest lift on a weighted basis, while French luxury company LVMH is one of the larger drags, along with ASML , Nestle and

Retail is the sector outperformer, up 0.7%, while travel and leisure and utilities are the worst off, down 0.1%-0.2%.

GRINCH (RE)APPEARS (0744 GMT)

Ignoring a hawkish Fed, investors attempted the briefest of Santa rallies this week but revised U.S. GDP data and relatively low claims for unemployment benefits have brought back worries of higher-for-longer interest rates.

And so the safe-haven U.S. dollar is back on the prowl, with Asian shares set to end in the red for a second straight week.

Investors will now focus on U.S. personal consumption expenditures data, due later on Friday, which will provide more clues on the direction of inflation as traders look ahead to 2023.

Some are clinging to the hope that central banks will likely pause interest rate hikes next year in the face of an economic slowdown.

But as Generali Investments strategists put it, central banks are still showing their teeth, committed to tackling inflation, and an outright policy pivot looks distant.

The yen managed to retain most of its gains against the dollar after the BOJ bombshell earlier this week, with data on Friday showing that Japan's consumer inflation hit a fresh 40-year high, adding to pressure on the central bank to alter its ultra-easy policy.

Meanwhile, COVID-19 infections in China are likely to hit their peak within a week, a health official said, as China's health system prepares for a surge in cases weeks after the country began dismantling its zero-COVID policy.

The saga around the collapse of the FTX crypto exchange rumbles on, with Sam Bankman-Fried released on a $250 million bond package while he awaits trial.

In the corporate world, chip stocks slumped worldwide after Micron's dour forecast on what the chipmaker called a "significant supply demand mismatch".

Tesla CEO and Twitter owner Elon Musk said he will not sell any more Tesla stock for about two years, as the EV maker's stock is on track for its worst-ever monthly performance.

Key developments that could influence markets on Friday:

Economic events: Spain Q3 GDP data, France November producer price data

'TIS THE SEASON AFTER ALL (0734 GMT)

European futures are rising around 0.3%, with the STOXX 600 set to wrap up the last week before Christmas in the green.

The London Stock Exchange will begin a market closing process from 1230 GMT today. European bourses remain open all day, barring Dublin, which also has a half day.

Though the index has added 0.59% since Monday, it is no where near enough to reverse the 3.2% drop last week amid a spate of central bank decisions and business activity data that pointed to a slowdown in growth.

The index remains 12.4% lower than where it started the year.

Attention is staying on China, which expects a peak in COVID-19 infections within a week, and on Japan, where the latest data showed core consumer inflation hitting a four-decade high.

Minutes on Friday showed Bank of Japan (BOJ) policymakers had discussed the potential market impact of a future exit from ultra-low interest rates, months before a surprise tweak to its yield control policy earlier this week.

More News
3 Jan 2024 16:52

LONDON MARKET CLOSE: Stocks down ahead of US Fed minutes

(Alliance News) - Stock prices in London closed lower on Wednesday, as investors nervously look ahead to the latest US Federal Reserve meeting minutes.

Read more
3 Jan 2024 11:07

Jefferies upgrades GSK to 'buy', cuts AstraZeneca to 'hold'

(Sharecast News) - Jefferies has upgraded its rating on GlaxoSmithKline to 'buy' and cut AstraZeneca to 'hold' as part of its review of the European pharma sector.

Read more
3 Jan 2024 10:16

IN BRIEF: Nuformix narrows annual loss as develops drug assets

Nuformix PLC - London-based developer of treatments for fibrosis and oncology via drug repurposing - Pretax loss narrows to GBP927,972 in 18 months that ended September 30 from GBP1.3 million in the 12 months that ended March 31, 2022, following its change of financial year-end. Has no meaningful revenue in either period, so reduced loss is due to lower administrative expenses.

Read more
3 Jan 2024 10:12

AIM WINNERS & LOSERS: C4X gets Astra payment; Getech wins eight deals

(Alliance News) - The following stocks are the leading risers and fallers on AIM in London on Wednesday.

Read more
3 Jan 2024 09:23

LONDON BROKER RATINGS: GSK raised to 'buy'; AstraZeneca cut to 'hold'

(Alliance News) - The following London-listed shares received analyst recommendations Wednesday morning and Tuesday:

Read more
3 Jan 2024 08:58

LONDON MARKET OPEN: Stocks mixed pre-Fed minutes, amid Asia losses

(Alliance News) - Stock prices in London opened mixed on Wednesday, ahead of US Federal Reserve meeting minutes and manufacturing PMI data for the US in the evening and afternoon respectively.

Read more
3 Jan 2024 08:04

C4X receives USD11 million from AstraZeneca following NRF2 trials

(Alliance News) - C4X Discovery Holdings PLC on Wednesday said it has received payment from AstraZeneca PLC following trials of the C4X respiratory disease therapy treatment.

Read more
3 Jan 2024 07:54

LONDON BRIEFING: Stocks to open flat pre-Fed minutes, jobs data

(Alliance News) - The FTSE 100 is expected to open flat on Wednesday, as London's flagship index celebrates its 40th anniversary, after mostly downbeat trading in Asia and a tech sell-off in New York.

Read more
2 Jan 2024 17:05

British equities slip on higher yields, financials drag

FTSE 100 down 0.2%, FTSE 250 off 0.9%

*

Read more
2 Jan 2024 12:01

LONDON MARKET MIDDAY: London stocks make largely soft start to 2024

(Alliance News) - Stock prices in London were mostly lower at midday on Tuesday in a slow start to the new year, reacting to the UK manufacturing sector finishing a tricky 2023 with a further contraction in December.

Read more
2 Jan 2024 11:00

Weight-loss drugs: Who, and what, are they good for?

Jan 2 (Reuters) - Powerful weight-loss medicines like Novo Nordisk's Wegovy leapt into public view in 2023, from social media to doctors' offices and cocktail parties, offering a new way to address record obesity rates.

Read more
2 Jan 2024 11:00

What other health conditions might weight-loss drugs treat?

Jan 2 (Reuters) - Novo Nordisk's blockbuster diabetes drug Ozempic and weight-loss therapy Wegovy are being studied to see whether they can improve health in other ways.

Read more
2 Jan 2024 08:48

LONDON MARKET OPEN: New Year begins largely green amid slew of PMIs

(Alliance News) - Stock prices in London opened mostly up on Tuesday, the first day of trading in 2024, reacting to slightly improved factory activity in China, with more manufacturing PMIs from major economies due.

Read more
2 Jan 2024 08:26

AstraZeneca and Sanofi received approval in China for RSV antibody

(Alliance News) - AstraZeneca PLC and Sanofi SA's long-acting monoclonal antibody Beyfortus received approval for use in China to prevent respiratory syncytial virus disease, Astra said on Tuesday.

Read more
2 Jan 2024 07:57

LONDON BRIEFING: AstraZeneca, Sanofi's RSV treatment approved in China

(Alliance News) - Stock prices in London are expected to open higher on Tuesday, reacting to a slight expansion in manufacturing activity in China and ahead of a slew of manufacturing PMI data including for the UK.

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.